Advanced Filters
noise
Found 811 clinical trials
j jianwen Guo, Dr

Proteomics Study of Mild Cognitive Impairment and Alzheimer's Disease

This study intends to adopt standardized and rigorous cross-sectional research, collect biological specimens (including blood, feces, urine, saliva and tongue coating) from eligible subjects, and use liquid chromatography/mass spectrometry (LC-MS/MS) technology to explore early warning indicators of protein in patients with mild cognitive impairment and Alzheimer's disease

55 years of age All Phase N/A

Digital Detection of Dementia (D Cubed) Studies: D3

The specific aim of the pragmatic trial is to evaluate the practical utility and effect of the PDM, the QDRS, and the combined approach (PDM + QDRS) in improving the annual rate of new documented ADRD diagnosis in primary care practices.

65 years of age All Phase N/A
B Brent Mausbach, PhD

A Dyadic Sleep Health Approach for Persons With Alzheimer's Disease and Caregivers

This is a randomized controlled trial over 5 years, using Stage II of the NIH-defined stage model for behavioral intervention development. We will evaluate the efficacy of the sleep intervention program (Care2Sleep) on sleep, health status measures, and quality of life (for dyads), and inflammation (for caregivers only). Eligible participants …

18 years of age All Phase N/A
P Prof. Dr. Jörg B. Schulz

German Dementia Registry

The German Dementia Registry (DEMREG) is a large-scale national prospective biomarker-based study for cognitive impairment and dementia, providing an integrated clinical research platform for research studies.

18 years of age All Phase N/A

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to …

50 - 85 years of age All Phase 2

A Study to Evaluate the Efficacy and Safety of AD-218

The purpose of this study is to evaluate the efficacy and safety of AD-218

19 years of age All Phase 3
C Cui bai Wei, Ph.D

Exploring the Predicting Biomarkers From Mild Cognitive Impairment to Dementia (EBMID)

Mild cognitive impairment (MCI) represents a transitional stage between healthy aging and dementia, and affects more than 15% of the population over the age of 60 in China. About 15% patients with MCI could progress into dementia after two years and about one-third develop into dementia within five years, which …

50 - 85 years of age All Phase N/A
L Luca Stingeni

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on background TCS who have had inadequate response to prior biologic or oral JAKi therapy. The purpose of this study is to measure the efficacy and safety of …

12 years of age All Phase 3
D Dustin B Hammers, PhD

Lifestyle Interventions for the Treatment of Early Onset Alzheimer's Disease Study

The purpose of this study is to generate preliminary data on the benefit of computerized cognitive training and Tai Chi- Qi Gong training in participants with Early-Onset Alzheimer's Disease. It is hypothesized that participants in the experimental training condition will perform better on outcomes related to cognition, functioning, and mood …

40 - 75 years of age All Phase N/A
M Madeleine Hackney, MD

Partnered Rhythmic Rehabilitation in Prodromal Alzheimer's Disease

Interventions that affect many different aspects of human ability rather than just one aspect of human health are more likely to be successful in preventing and treating Alzheimer's disease (AD). Functional decline in AD is severely impacted by impaired ability to do physical actions while having to make decisions and …

50 - 80 years of age All Phase N/A

Simplify language using AI